628 related articles for article (PubMed ID: 25487315)
1. Selected extracellular microRNA as potential biomarkers of multiple sclerosis activity--preliminary study.
Kacperska MJ; Jastrzebski K; Tomasik B; Walenczak J; Konarska-Krol M; Glabinski A
J Mol Neurosci; 2015 May; 56(1):154-63. PubMed ID: 25487315
[TBL] [Abstract][Full Text] [Related]
2. Differential microRNA expression in blood in multiple sclerosis.
Søndergaard HB; Hesse D; Krakauer M; Sørensen PS; Sellebjerg F
Mult Scler; 2013 Dec; 19(14):1849-57. PubMed ID: 23773985
[TBL] [Abstract][Full Text] [Related]
3. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
4. Plasmatic microRNA as Potential Biomarkers of Multiple Sclerosis: Literature Review.
Kacperska MJ; Walenczak J; Tomasik B
Adv Clin Exp Med; 2016; 25(4):775-9. PubMed ID: 27629854
[TBL] [Abstract][Full Text] [Related]
5. miR-326 and miR-26a, two potential markers for diagnosis of relapse and remission phases in patient with relapsing-remitting multiple sclerosis.
Honardoost MA; Kiani-Esfahani A; Ghaedi K; Etemadifar M; Salehi M
Gene; 2014 Jul; 544(2):128-33. PubMed ID: 24792898
[TBL] [Abstract][Full Text] [Related]
6. Micro-RNA-96 and interleukin-10 are independent biomarkers for multiple sclerosis activity.
Sedeeq MS; El-Nahrery EMA; Shalaby N; Hussein M; Shehata H; El Aal RA; Abdel Ghaffar NF; Mohamed MM
J Neurol Sci; 2019 Aug; 403():92-96. PubMed ID: 31238191
[TBL] [Abstract][Full Text] [Related]
7. Association between circulating MicroRNAs (hsa-miR-92a-1* and hsa-miR-454) and multiple sclerosis phenotypes and activity status.
Moharram AA; Amer HA; Bakr SI; Fouad NT; Zamzam D; M R
Egypt J Immunol; 2022 Apr; 29(2):10-18. PubMed ID: 35436050
[TBL] [Abstract][Full Text] [Related]
8. Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity.
Regev K; Healy BC; Khalid F; Paul A; Chu R; Tauhid S; Tummala S; Diaz-Cruz C; Raheja R; Mazzola MA; von Glehn F; Kivisakk P; Dupuy SL; Kim G; Chitnis T; Weiner HL; Gandhi R; Bakshi R
JAMA Neurol; 2017 Mar; 74(3):275-285. PubMed ID: 28114622
[TBL] [Abstract][Full Text] [Related]
9. Expression levels of IL-17/IL-23 cytokine-targeting microRNAs 20, 21, 26, 155, and Let-7 in patients with relapsing-remitting multiple sclerosis.
Balkan E; Bilge N
Neurol Res; 2021 Sep; 43(9):778-783. PubMed ID: 34130607
[No Abstract] [Full Text] [Related]
10. Challenges and standardization of microRNA profiling in serum and cerebrospinal fluid in dogs suffering from non-infectious inflammatory CNS disease.
Cirera S; Andersen-Ranberg EU; Langkilde S; Aaquist M; Gredal H
Acta Vet Scand; 2019 Dec; 61(1):57. PubMed ID: 31796072
[TBL] [Abstract][Full Text] [Related]
11. Differential urinary microRNA expression analysis of miR-1, miR-215, miR-335, let-7a in childhood nephrotic syndrome.
Dandapani MC; Venkatesan V; Charmine P; Geminiganesan S; Ekambaram S
Mol Biol Rep; 2022 Jul; 49(7):6591-6600. PubMed ID: 35553329
[TBL] [Abstract][Full Text] [Related]
12. Discovery and validation of extracellular/circulating microRNAs during idiopathic pulmonary fibrosis disease progression.
Yang G; Yang L; Wang W; Wang J; Wang J; Xu Z
Gene; 2015 May; 562(1):138-44. PubMed ID: 25725128
[TBL] [Abstract][Full Text] [Related]
13. Erythrocyte microRNA sequencing reveals differential expression in relapsing-remitting multiple sclerosis.
Groen K; Maltby VE; Lea RA; Sanders KA; Fink JL; Scott RJ; Tajouri L; Lechner-Scott J
BMC Med Genomics; 2018 May; 11(1):48. PubMed ID: 29783973
[TBL] [Abstract][Full Text] [Related]
14. Housekeeping genes for studies of plasma microRNA: A need for more precise standardization.
Rice J; Roberts H; Rai SN; Galandiuk S
Surgery; 2015 Nov; 158(5):1345-51. PubMed ID: 26094174
[TBL] [Abstract][Full Text] [Related]
15. Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases.
Sharaf-Eldin WE; Kishk NA; Gad YZ; Hassan H; Ali MAM; Zaki MS; Mohamed MR; Essawi ML
J Neurol Sci; 2017 Dec; 383():188-198. PubMed ID: 29246612
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-572 expression in multiple sclerosis patients with different patterns of clinical progression.
Mancuso R; Hernis A; Agostini S; Rovaris M; Caputo D; Clerici M
J Transl Med; 2015 May; 13():148. PubMed ID: 25947625
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Selected MicroRNAs Expression in Remission Phase of Multiple Sclerosis and Their Potential Link to Cognition, Depression, and Disability.
Niwald M; Migdalska-Sęk M; Brzeziańska-Lasota E; Miller E
J Mol Neurosci; 2017 Dec; 63(3-4):275-282. PubMed ID: 29043654
[TBL] [Abstract][Full Text] [Related]
18. Variability in microRNA recovery from plasma: Comparison of five commercial kits.
Brunet-Vega A; Pericay C; Quílez ME; Ramírez-Lázaro MJ; Calvet X; Lario S
Anal Biochem; 2015 Nov; 488():28-35. PubMed ID: 26271186
[TBL] [Abstract][Full Text] [Related]
19. Differential Expression of Serum Extracellular Vesicle miRNAs in Multiple Sclerosis: Disease-Stage Specificity and Relevance to Pathophysiology.
Cuomo-Haymour N; Bergamini G; Russo G; Kulic L; Knuesel I; Martin R; Huss A; Tumani H; Otto M; Pryce CR
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163583
[TBL] [Abstract][Full Text] [Related]
20. Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
Muñoz-Culla M; Irizar H; Castillo-Triviño T; Sáenz-Cuesta M; Sepúlveda L; Lopetegi I; López de Munain A; Olascoaga J; Baranzini SE; Otaegui D
Mult Scler; 2014 Dec; 20(14):1851-9. PubMed ID: 24852919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
